Zhao Huan, Lin Qifeng, Huang Li, Zhai Yunfeng, Liu Yuan, Deng Yan, Su Enben, He Nongyue
State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Nanoscale. 2021 Feb 7;13(5):3275-3284. doi: 10.1039/d0nr08008j. Epub 2021 Feb 3.
A novel enhanced chemiluminescent immunoassay (CLIA) for ultrasensitive and excellent precisive determination of cardiac troponin I (cTnI) was reported. The method made full use of poly[(N-isopropyl acrylamide)-co-(methacrylic acid)] (P(NIPAM-co-MAA)) microspheres as new potential signal enhancers and magnetic fluorescent nanoparticles as internal standards for better precision. This protocol involved a sandwich format, in which the antigen in the sample was captured by the immobilized antibodies on the surface of magnetic fluorescent beads and recognized by the other antibodies labeled with acridinium ester (AE)-loaded P(NIPAM-co-MAA) microspheres. The combination of the remarkable sensitivity of the enhanced CLIA method and the use of P(NIPAM-co-MAA) microspheres as anti-cTnI carriers for acridinium ester signal amplification provided an extremely sensitive limit of blank (LoB) at 0.097 pg mL, a limit of detection (LoD) at 0.116 pg mL, and a limit of quantitation (LoQ) at 0.606 pg mL, much greater than those achieved by the classical chemiluminescence immunoassay (CLIA, Getein). Moreover, the intra-day variable coefficient can be improved to 1.21-2.12%, and inter-day variability was 2.01-3.49% under the application of magnetic fluorescent beads as an internal standard. The sensitivity and precision have reached a high level, comparable with the current commercial detection kits. The results showed a good correlation with a commercial chemiluminescence assay (CLIA, Abbott), with a correlation coefficient of 0.9883. This proposed method has been successfully applied to the clinical determination of cTnI in the human serum.
报道了一种用于超灵敏、精确测定心肌肌钙蛋白I(cTnI)的新型增强化学发光免疫分析(CLIA)方法。该方法充分利用聚[(N-异丙基丙烯酰胺)-共-(甲基丙烯酸)](P(NIPAM-co-MAA))微球作为新型潜在信号增强剂,并使用磁性荧光纳米颗粒作为内标以提高精密度。该方案采用夹心形式,其中样品中的抗原被固定在磁性荧光珠表面的抗体捕获,并被标记有吖啶酯(AE)负载的P(NIPAM-co-MAA)微球的其他抗体识别。增强CLIA方法的显著灵敏度与使用P(NIPAM-co-MAA)微球作为吖啶酯信号放大的抗cTnI载体相结合,提供了极低的空白限(LoB)为0.097 pg/mL,检测限(LoD)为0.116 pg/mL,定量限(LoQ)为0.606 pg/mL,远高于经典化学发光免疫分析(CLIA,Getein)所达到的水平。此外,在使用磁性荧光珠作为内标的情况下,日内变异系数可提高到1.21 - 2.12%,日间变异为2.01 - 3.49%。灵敏度和精密度已达到较高水平,与目前的商业检测试剂盒相当。结果与商业化学发光分析(CLIA,Abbott)显示出良好的相关性,相关系数为0.9883。该方法已成功应用于人体血清中cTnI的临床测定。